Enparticle Co., Ltd. (CEO Ko Jeong-sang) announced that it will participate in the ‘6 International Advanced Medical Devices and Medical Industry Exhibition (KOAMEX 30)’, which will be held at EXCO in Daegu for three days from Friday, June 7th to Sunday, July 2nd. .
Enparticle is a company that has developed platform technology for mass production of micro and nano particles using microfluidic technology. Based on this, it is implemented as equipment to manufacture vaccines and treatments in the form of mRNA-carrying LNP (Lipid Nano Particle) and is provided to various fields such as medicine, cosmetics, and food.
The company explained that this safe and high-quality pharmaceutical manufacturing technology adds value to particles and further contributes to improving human health.
At this exhibition, Enparticle introduces its LNP manufacturing equipment, ‘enCELL’. This is equipment for manufacturing LNPs carrying mRNA. It reflects microfluidic technology that adjusts the size and uniformity of particles in the range of 50nm to 200nm through stable flow in a hair-sized channel, and precisely controls the encapsulation rate and physical properties.
At the same time, it has differentiated itself from existing facilities with its own particle mass production technology and has the advantage of being able to apply the same process conditions when manufacturing scale-up LNPs. The supply price is also 40% compared to foreign equipment, and disposable LNP manufacturing chips are only 1%, and maintenance costs can be reduced by up to 30%, boasting excellent cost efficiency.
An Enparticle official said, “For foreign LNP manufacturing equipment, the cost of a disposable LNP manufacturing chip amounts to 10 won, and the annual consumption increases proportionally depending on the number of equipment sold and the amount of chip usage.” He added, “Due to the characteristics of customers in the bio and pharmaceutical fields, Although there is a high level of dependence on the equipment used, there is a huge burden on consumables and maintenance costs. “On the other hand, our Ncell is capable of developing products that are superior to foreign equipment through its original patented technology, and is also cost-effective, making it an excellent alternative,” he added.
He continued, “According to industry forecasts, the global LNP market size is expected to grow to $2020 million by 1.04 after being valued at $2026 million in 8.29,” adding, “Among them, the test bed of Oxford University in the UK and Ncell equipment will be utilized. He added, “We are also taking steps to pioneer the global market, including completing the signing of an agreement last January with the focus on cooperation in joint research on biopharmaceuticals.”
Meanwhile, the main exhibition items of ‘KOAMEX 2023’ hosted by Daegu Metropolitan City and K-MEDI Hub are as follows. △Diagnostic and diagnostic devices such as scanners, measuring devices, and imaging devices △Clinical and inspection devices △Surgical and recycling devices △Hospital facilities and emergency equipment △Medical devices, parts, and services △Pharmaceutical devices △Medical services, SW